Nasopharyngeal carcinoma
Conditions
Interventions
One group:Concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with 4 cycles of cisplatin and docetaxel
Sponsors
Department of Otolaryngology Head and Neck Surgery, PLA General Hospital
Eligibility
Sex/Gender
All
Age
17 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients have no previous malignancy and a histologically proven squamous cell carcinoma of the stage III-IV larynx or hypopharynx (American Joint Committee disease stages). Eligibility criteria were age between 18 and 70 years, good performance status of ECOG (Eastern Cooperative Oncology Group) 0 or 1; life expectancy longer than 6 months; Adequate bone marrow, renal and hepatic function. No prior chemotherapy, radiotherapy, or surgery.
Exclusion criteria
Exclusion criteria: Patients with synchronous primary cancers or/and metastasis disease or/and had received targeted therapy are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safty;Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate;Progression-free survival (PFS);Locoregional failure-free rate (LFFR);Distant failure-free rate (DFFR); | — |
Countries
China
Contacts
Public ContactXinxin Zhang
Outcome results
None listed